RadNet (RDNT) has agreed to acquire iCad (ICAD) in an all-stock deal valued at roughly $103 million, the companies said late Tuesday.
Shares of iCad jumped more than 72% in recent after-hours activity, while those of RadNet were down 2%.
As part of the agreement, iCad shareholders will receive 0.0677 shares of RadNet common stock for each iCad share they own, valuing it at $3.61 per share, a 98% premium based on the closing prices Monday.
The acquisition is expected to merge advanced artificial intelligence technologies from both companies to strengthen early breast cancer detection and streamline diagnostic workflows, the companies said.
The transaction, unanimously approved by both companies' boards, is expected to close in Q2 or Q3, pending iCad stockholder approval and customary closing conditions, according to a joint statement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。